GSK seeks to protect Advair through GBP1.2bn acquisition of Vectura

The British newspaper The Telegraph has reported today that the pharma giant GSK is about to offer GBP1.2bn for UK-based Vectura. The reported offer corresponds to GBP1.75 per share, that is a 53% premium over yesterday’s closing price. A takeover by GSK has been rumored for months, yet it has become a real option only now, and shares have soon increased by 4.5% in pre-market trading. Vectura manufactures asthma inhalers and cooperates with Hikma to develop the generic drug to GSK’s blockbuster Advair, expected to be approved by FDA as early as Q1 2018.
(Source: The Telegraph)